Australian company Emyria (ASX:EMD) has announced interim clinical results from an analysis of its MDMA-assisted therapy for post-traumatic stress disorder program, which commenced in October 2023.
The company said the early findings are from an initial cohort of eight patients with moderate to severe post-traumatic stress disorder (PTSD) symptoms and who were getting limited relief from standard treatment before enrollment.
It said all eight demonstrated improved patient outcomes at the end of their active treatment. Clinically and statistically significant improvements were observed in PTSD symptoms and quality of life. Five additional patients are currently enrolled and undergoing treatment, with the program progressing towards its recruitment goal of 70 initial patients.
